Last reviewed · How we verify
Lauric Acid (dodecanoic acid)
At a glance
| Generic name | dodecanoic acid |
|---|---|
| Drug class | dodecanoic acid |
| Target | G-protein coupled receptor 84, Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
- Gastrointestinal complaints
- Skin ailments
- Visual problems
- Glucose abnormalities
Serious adverse events
- Allergic reactions
- Idiosyncratic reactions
Key clinical trials
- Fatty Acids in Airway Smooth Muscle of Asthmatics (NA)
- Topical Coconut Oil Application and Incidence of Sepsis in Neonates (NA)
- Efficacy of Lauric Acid, a Dietary Fatty Acid, in Modifying the Latent Reservoir of HIV (NA)
- Nutritional Supplement for Patients With Severe Infection (NA)
- A Pilot Study to Evaluate the Efficacy and Safety of Lactobacillus Species Suppositories on Vaginal Health and pH (PHASE4)
- The Effect of Dietary Lauric Acid on the Production of the LRH-1 Ligand, Dilauroylphosphatidylcholine (NA)
- Sour Taste Intensity Matching With Fatty Acids Taste (NA)
- Phototherapy in DM Amputation Ulcers. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lauric Acid CI brief — competitive landscape report
- Lauric Acid updates RSS · CI watch RSS
- portfolio CI